AR108562A1 - Método para la preparación del conjugado hialuronidasa con derivados de piperazina de polietileno y la aplicación del conjugado obtenido - Google Patents

Método para la preparación del conjugado hialuronidasa con derivados de piperazina de polietileno y la aplicación del conjugado obtenido

Info

Publication number
AR108562A1
AR108562A1 ARP160103691A ARP160103691A AR108562A1 AR 108562 A1 AR108562 A1 AR 108562A1 AR P160103691 A ARP160103691 A AR P160103691A AR P160103691 A ARP160103691 A AR P160103691A AR 108562 A1 AR108562 A1 AR 108562A1
Authority
AR
Argentina
Prior art keywords
conjugate
preparation
application
conjugation
ranges
Prior art date
Application number
ARP160103691A
Other languages
English (en)
Inventor
Nino Temurievna Karaputadze
Alexander Vladimirovich Kozukov
Sergei Alekseevich Medvedev
Temuri Musaevich Karaputadze
Arkadii Vasilevich Nekrasov
Original Assignee
Obshchestvo S Ogranichennoy Otvetstvennostyu «Npo Petrovaks Farm»
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Obshchestvo S Ogranichennoy Otvetstvennostyu «Npo Petrovaks Farm» filed Critical Obshchestvo S Ogranichennoy Otvetstvennostyu «Npo Petrovaks Farm»
Publication of AR108562A1 publication Critical patent/AR108562A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F26/00—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F26/06—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a heterocyclic ring containing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment
    • C08F8/02—Alkylation
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment
    • C08F8/06—Oxidation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)

Abstract

Método para obtener preparaciones de enzimas inmovilizadas, en particular a la preparación y la aplicación del conjugado activo de la enzima con un vehículo polimérico. Dicho conjugado posee las propiedades del fármaco Longidaza e inhibe la hiperplasia del tejido conectivo, y acción anti-inflamatoria, además puede usarse para fabricar fármacos estables, activos y seguros en el uso de acción prolongada en la forma de un supositorio, un ungüento, una inyección o una crema cosmética, y para producir fármacos de uso veterinario. Este método consiste en la conjugación de la hialuronidasa con un copolímero hidrosoluble que utiliza el método de carbodiimida o azida. La conjugación se lleva a cabo con el uso del copolímero de N-óxido poli-1,4-etilenpiperazona, (N-carboximetil)-1,4-etilenpiperazina o su hidrazida y la 1,4-etilenpierazina de la fórmula general (1), donde n oscila desde 40% hasta 90% del número total de células; m oscila desde 3% hasta 40% del número total de células; n + m + 1 = 100%.
ARP160103691A 2015-12-04 2016-12-01 Método para la preparación del conjugado hialuronidasa con derivados de piperazina de polietileno y la aplicación del conjugado obtenido AR108562A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2015152036A RU2616528C1 (ru) 2015-12-04 2015-12-04 Способ получения конъюгата гиалуронидазы с производными полиэтиленпиперазина и применение полученного конъюгата

Publications (1)

Publication Number Publication Date
AR108562A1 true AR108562A1 (es) 2018-09-05

Family

ID=58642685

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160103691A AR108562A1 (es) 2015-12-04 2016-12-01 Método para la preparación del conjugado hialuronidasa con derivados de piperazina de polietileno y la aplicación del conjugado obtenido

Country Status (19)

Country Link
US (1) US11364283B2 (es)
EP (1) EP3384917B1 (es)
JP (1) JP6683827B2 (es)
KR (2) KR20200131355A (es)
CN (1) CN108697732B (es)
AR (1) AR108562A1 (es)
CA (1) CA3007389C (es)
EA (1) EA030139B1 (es)
GE (1) GEP20207131B (es)
HK (1) HK1259290A1 (es)
HU (1) HUE056845T2 (es)
LT (1) LT3384917T (es)
MD (1) MD4637C1 (es)
RS (1) RS62659B1 (es)
RU (1) RU2616528C1 (es)
SI (1) SI3384917T1 (es)
TR (1) TR201807851T1 (es)
UA (1) UA121425C2 (es)
WO (1) WO2017095264A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7463110B2 (ja) * 2017-06-29 2024-04-08 ユニヴァーシティ オブ ワシントン Ｎ－オキシド及びエクトインモノマー、ポリマー、それらの組成物及び関連方法
RU2737271C2 (ru) * 2018-06-27 2020-11-26 ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НПО Петровакс Фарм" Сополимеры ди-N-оксидов поли-1,4-этиленпиперазина и способы их получения
CN111978404A (zh) * 2020-08-11 2020-11-24 西北大学 基于Halo-tag特异性脱卤反应的蛋白质一步定向固定化方法
KR102481458B1 (ko) 2021-12-15 2022-12-27 홍재혁 문신기구

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2801723B2 (ja) 1990-01-26 1998-09-21 花王株式会社 新規ベタイン及びそれを含有する分散剤
RU2073031C1 (ru) * 1990-08-06 1997-02-10 Некрасов Аркадий Васильевич Производные поли-1,4-этиленпиперазина, обладающие иммуномодулирующей, противовирусной и антибактериальной активностями
EP0789586B1 (en) * 1993-09-10 2001-07-04 Petrovax, Inc. Compounds for the prevention and treatment of helminth infections
RU2112542C1 (ru) * 1997-02-28 1998-06-10 Аркадий Васильевич Некрасов Препарат для лечения патологических состояний соединительной ткани
RU2185388C2 (ru) * 2000-06-28 2002-07-20 Карапутадзе Темури Мусаевич Способ получения поли-1,4-этиленпиперазина и его производных
NZ601248A (en) * 2008-04-14 2014-06-27 Halozyme Inc Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
RU2417097C2 (ru) * 2008-04-24 2011-04-27 Валерия Леонидовна Багирова Фармацевтическая композиция, содержащая гиалуронидазу и липосомы для наружного применения
RU2428991C9 (ru) 2010-06-24 2011-12-27 ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НПО Петровакс Фарм" Сополимеры гетероцепных алифатических поли-n-оксидов, вакцинирующие и лекарственные средства на их основе
RU2556378C2 (ru) * 2013-07-11 2015-07-10 ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НПО Петровакс Фарм" Конъюгат гликопротеина, обладающего активностью эритропоэтина, с производными n-оксида поли-1,4-этиленпиперазина (варианты), фармацевтическая композиция и способ получения конъюгата

Also Published As

Publication number Publication date
CN108697732A (zh) 2018-10-23
EP3384917A1 (en) 2018-10-10
US11364283B2 (en) 2022-06-21
HK1259290A1 (zh) 2019-11-29
MD4637C1 (ro) 2020-01-31
WO2017095264A1 (ru) 2017-06-08
CA3007389C (en) 2021-01-12
UA121425C2 (uk) 2020-05-25
HUE056845T2 (hu) 2022-03-28
EA201650048A1 (ru) 2017-06-30
MD20180043A2 (ro) 2018-11-30
RS62659B1 (sr) 2021-12-31
CN108697732B (zh) 2021-02-26
RU2616528C1 (ru) 2017-04-17
SI3384917T1 (sl) 2022-01-31
KR20200131355A (ko) 2020-11-23
GEP20207131B (en) 2020-07-10
JP2019501217A (ja) 2019-01-17
CA3007389A1 (en) 2017-06-08
MD4637B1 (ro) 2019-06-30
TR201807851T1 (tr) 2018-06-21
KR20180090339A (ko) 2018-08-10
KR102358980B1 (ko) 2022-02-08
EP3384917B1 (en) 2021-09-15
LT3384917T (lt) 2021-11-25
EA030139B1 (ru) 2018-06-29
US20180344815A1 (en) 2018-12-06
EP3384917A4 (en) 2019-09-04
JP6683827B2 (ja) 2020-04-22

Similar Documents

Publication Publication Date Title
AR108562A1 (es) Método para la preparación del conjugado hialuronidasa con derivados de piperazina de polietileno y la aplicación del conjugado obtenido
ZA202202712B (en) Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
MX2021014509A (es) Composiciones farmaceuticas que comprenden meloxicam.
CY1117969T1 (el) Αντιψυχωτικη ενεσιμη συνθεση μακρας διαρκειας δρασης
MX2015012433A (es) Matriz de microestructura para suministro de agentes activos.
CY1117735T1 (el) Σκευασμα αντισωματος
BR112017014599A2 (pt) dímeros de benzodiazepina, conjugados dos mesmos, e métodos de preparação e uso
ES2721898T3 (es) Formulaciones estables para liofilizar partículas terapéuticas
EA201690618A1 (ru) Ингибиторы тирозинкиназы брутона
CL2019001447A1 (es) Preparación de complejos sólidos de ciclodextrina para suministro de ingredientes farmacéuticos activos oftálmicos.
EA201792487A1 (ru) Композиции гидроксипропил-бета-циклодекстринов и способы
UY36542A (es) Formulaciones farmacéuticas para anticuerpos anti-tnf-alfa
EA201290976A1 (ru) Ненуклеозидные ингибиторы обратной транскриптазы
AR072668A1 (es) Encapsulacion de agentes biologicamente activos
BR112015017246A8 (pt) composição farmacêutica aquosa, seu uso e seringa
ECSP18060848A (es) Derivados de 3-((hetero)aril)-alquil-8-amino-2-oxo-1,3-diaza-espiro-[ 4.5]-decano
CY1122882T1 (el) Παραγωγα 3-(καρβοξυαιθυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου
EA201890436A1 (ru) Жидкая полимерная система доставки для длительного введения лекарственных средств
EP4335851A3 (en) Pharmaceutical formulations and methods of use thereof
CO2018008449A2 (es) Derivados de 3-(carboximetil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
CY1124294T1 (el) Τοπικο σκευασμα
AR105223A1 (es) Compuestos químicos
ECSP18060834A (es) Derivados de 3-((hetero)aril)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano
CO2020004407A2 (es) Formulaciones de espora de nutriente y usos de las mismas
AR102571A1 (es) Unidad de dispositivo con medicamento conteniendo quinagolida para uso en endometriosis, método